Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:28:07 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:ACST - ACASTI PHARMA INC - http://www.acastipharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ACST - Q0.52.39·3.370.13.03    3.8392  1.72May 02Feb 1215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-02-12 08:00U:ACSTNews ReleaseAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
2024-02-01 08:00U:ACSTNews ReleaseAcasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
2023-12-13 08:00U:ACSTNews ReleaseAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
2023-11-13 08:00U:ACSTNews ReleaseAcasti Announces Second Quarter 2024 Financial Results and Business Highlights
2023-10-23 08:00U:ACSTNews ReleaseAcasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
2023-10-04 08:00U:ACSTNews ReleaseAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
2023-09-26 08:00U:ACSTNews ReleaseAcasti Announces $7.5 Million Private Placement Equity Financing
2023-09-06 08:00U:ACSTNews ReleaseAcasti to Participate in the H.C. Wainwright Global Investment Conference
2023-08-11 07:00U:ACSTNews ReleaseAcasti Announces First Quarter 2024 Financial Results and Business Highlights
2023-08-09 16:05U:ACSTNews ReleaseAcasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
2023-07-10 09:00U:ACSTNews ReleaseAcasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
2023-07-07 08:00U:ACSTNews ReleaseAcasti Pharma Announces 1-for-6 Reverse Stock Split
2023-07-05 09:00U:ACSTNews ReleaseAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
2023-06-23 07:00U:ACSTNews ReleaseAcasti Pharma Reports Fiscal Year 2023 Operational Results
2023-06-22 09:00U:ACSTNews ReleaseAcasti Announces Appointment of New Scientific Advisory Board Members
2023-05-17 09:00U:ACSTNews ReleaseAcasti to Participate in the Lytham Partners Spring 2023 Investor Conference
2023-05-08 07:00U:ACSTNews ReleaseAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025